Current Report Filing (8-k)
November 08 2016 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 2, 2016
BIOSCRIP, INC.
(Exact name of Registrant as specified in
its charter)
Delaware
|
|
001-11993
|
|
05-0489664
|
(State of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1600 Broadway, Suite 950, Denver, Colorado
|
|
80202
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (720) 697-5200
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02. Results of Operations and
Financial Condition.
On November 7, 2016,
BioScrip, Inc. (the “Company”) issued a press release reporting its 2016 third quarter financial results. A copy of
the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The press release includes
certain non-GAAP financial measures as described therein. As required by Regulation G, reconciliation between any non-GAAP financial
measures presented and the most directly comparable GAAP financial measures is also provided.
Item 5.02. Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 2, 2016,
Richard M. Smith resigned from the Board of Directors of the Company (the “Board”), effective November 3, 2016.
Item 8.01. Other
Events.
As previously announced,
the Company will host a conference call to discuss its 2016 third quarter financial results on November 8, 2016, at 11:00 a.m.
Eastern Time. Interested parties may participate in the conference call by dialing 888-372-9592 (U.S.) or by accessing a link on
the Company’s website at www.bioscrip.com 5-10 minutes prior to the start of the call. A replay of the conference call will
be available for two weeks after the call’s completion by dialing 855-859-2056 (U.S.) and entering conference call ID number
1061955. An audio webcast and archive will also be available for 30 days under the “Investor Relations” section of
the Company’s website.
Item 9.01. Financial Statements and
Exhibits
(d) Exhibits
See the Exhibit Index, which is hereby incorporated
by reference.
As provided in General
Instruction B.2 to Form 8-K, the information furnished in Item 2.02 and in Exhibit 99.1 hereto, as it relates to the Company’s
financial results for the quarter ended September 30, 2016, shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under
that Section and shall not be deemed incorporated by reference into any filing of the Company with the Securities and Exchange
Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly provided by specific
reference in such filing
.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
BIOSCRIP, INC.
|
|
|
|
|
|
|
|
|
|
Date: November 7, 2016
|
|
/s/ Kathryn Stalmack
|
|
|
By:
|
Kathryn Stalmack
|
|
|
|
Senior Vice President, General Counsel and Secretary
|
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release issued by the Company, dated November 7, 2016
|
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Sep 2023 to Sep 2024